Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 8930 results

  1. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development Reference number: GID-TA11439 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Teprotumumab for treating thyroid eye disease [ID6432]

    In development Reference number: GID-TA11531 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

    Awaiting development Reference number: GID-TA11828 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  7. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

    Awaiting development Reference number: GID-TA10777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

    In development Reference number: GID-TA11768 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  10. Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  11. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  12. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

    In development Reference number: GID-TA11422 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    Awaiting development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development Reference number: GID-DG10083 Expected publication date: TBC

    Diagnostics guidance
    In development

  15. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-DG10038 Expected publication date: TBC

    Diagnostics guidance
    In development